TLDR
- Abbott reported Q1 EPS of $1.15, matching analyst estimates of $1.14â$1.15
- Revenue came in at $11.16B, beating the $11B consensus estimate
- Cancer diagnostics unit, boosted by the Exact Sciences acquisition, helped drive results
- Medical device unit, Abbott’s largest segment, continued to perform well
- Q2 EPS guidance of $1.25â$1.31 came in slightly below the $1.32 analyst consensus
Abbott Laboratories posted first-quarter results on April 16 that edged past Wall Street’s revenue expectations, with its newly acquired cancer diagnostics business adding a lift.
Abbott Labs Q1 2026 Earnings
– Adj EPS $1.15 (est $1.15)
– Net Sales $11.16B (est $11.01B)
– Sees Q2 Adj EPS $1.25 To $1.31 (est $1.31)
– Sees FY Organic Sales +6.5% To +7.5% (est +6.87%)
— First Squawk (@FirstSquawk) April 16, 2026
The company reported adjusted EPS of $1.15 for the quarter. That matched one estimate of $1.15 and came in a penny above another consensus figure of $1.14, depending on the data source.
Total revenue for the quarter hit $11.16 billion, ahead of the $11 billion analysts had expected.
The stock closed at $101.56 heading into earnings. ABT is down 16.59% over the past three months and has lost 22.46% over the past year.
The Exact Sciences acquisition played a role in this quarter’s numbers. Abbott agreed to buy the cancer-test maker in November for $105 a share in a deal valued at up to $23 billion. The deal closed in March 2026.
That deal marked one of Abbott’s largest acquisitions and a push into the cancer diagnostics market. Results from that unit contributed to the Q1 beat.
Medical Devices Stay Strong
Abbott’s medical device unit remains its largest by revenue. It continued to deliver in Q1, helping underpin the overall top-line beat.
The company has leaned on its device business as a core revenue driver for several quarters now. That trend held through the first three months of 2026.
Guidance Comes In Just Below Expectations
For Q2 2026, Abbott guided for EPS of $1.25 to $1.31. The analyst consensus sat at $1.32, putting the midpoint of Abbott’s range a touch below Wall Street’s target.
For the full year, Abbott sees EPS of $5.38 to $5.58. The analyst consensus is $5.47, which falls within that range.
Abbott had zero positive EPS revisions and 18 negative EPS revisions in the last 90 days. That’s a shift from the prior quarter’s “great performance” financial health rating â InvestingPro now rates Abbott’s financial health as “good performance.”
The revenue beat offers some reassurance, even if the guidance range didn’t fully satisfy expectations. Abbott’s Q1 top-line performance was the cleaner part of this report.
The full-year EPS consensus of $5.47 sits within Abbott’s guided range of $5.38 to $5.58, which gives some room for the company to meet or beat that figure as the year plays out.
đ¨ Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. Weâre also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
